What Doliprane Treats: Main Uses and Benefits

Doliprane (Frovatriptan) is commonly used for the acute symptomatic treatment of migraine episodes in adults, including those that manifest with or without an aura. This medication is utilized in cases where symptomatic support is needed to address symptoms related to heightened physiological activity.

---

Relief from Pulsating Pain and Associated Distress

The primary therapeutic benefit assists with addressing symptoms related to physical discomfort, such as the moderate to severe pulsating head pain of migraine. It helps address symptom clusters that may become intense or disruptive, including the accompanying gastrointestinal distress (nausea and vomiting) and sensory distress (sensitivity to light and sound). The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as those requiring abortive management.

Providing Sustained Symptomatic Comfort

The treatment is relevant in conditions characterized by periods of heightened symptoms, particularly for patients prone to recurrent episodes. It provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and contributes to improved day-to-day comfort during symptomatic periods. This treatment is considered relevant for easing symptoms associated with recurrent episodes.

---

Quick Fact: Symptom Management Focus Doliprane (Frovatriptan) is applied in clinical settings that involve acute symptom patterns, and plays a role in managing the symptoms that interfere with daily functioning, including the throbbing pain, nausea, and sensitivity to light and sound.

Regulatory References

1. NIH MedlinePlus Drug Information on Frovatriptan

Doliprane, a brand name for the pain reliever and fever reducer paracetamol (acetaminophen), is generally safe for a wide range of individuals when used as directed.

Who Can Use Doliprane (Paracetamol)

Group	Indication
Adults and Children	To treat pain (headache, muscle ache, dental pain) and fever associated with colds or flu.
Pregnant or Breastfeeding Individuals	Generally considered safe at the lowest effective dose for the shortest possible duration, under medical guidance.
Infants	Specific formulations (e.g., suppositories, syrup) are available, with dosage based strictly on weight and age, not just age.

---

Who Should NOT Use Doliprane or Use with Caution

Paracetamol is contraindicated for individuals with a known allergy to paracetamol or any other component of the formulation. Caution and medical advice are mandatory for patients with:

• Severe liver disease or active liver failure, as paracetamol is primarily metabolized by the liver.
• Severe kidney failure (renal impairment).
• Chronic alcohol abuse, which significantly increases the risk of liver toxicity.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency (requires caution).

Interactions with other medicines and products

The official interaction profile for Doliprane (Frovatriptan) is defined by two primary domains: pharmacodynamic activity and metabolic clearance. Co-administration with other vasoconstrictive agents is strictly contraindicated. This category includes all Ergotamine derivatives (such as methysergide) and other Serotonin 5- HT1 Receptor Agonists (Triptans), due to the documented risk of additive and prolonged vasospasm that can potentially lead to ischemic events. To mitigate this risk, a mandatory separation of at least 24 hours must occur between the administration of Frovatriptan and any ergotamine-type medication.

A separate pharmacodynamic risk involves the potential for Serotonin Syndrome. This is noted when Frovatriptan is combined with other serotonergic agents, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), a caution that is also extended to co-administration with the herbal product St John's Wort.

Regarding pharmacokinetic interactions, the strong CYP1A2 inhibitor Fluvoxamine is documented to increase Frovatriptan's overall exposure (AUC and C max) by modulating the drug's primary metabolic pathway. Furthermore, Frovatriptan exposure is officially noted as increased with Propranolol and in individuals taking combined oral contraceptives. Food intake does not alter the overall amount of Frovatriptan absorbed, but it is documented to delay the time to peak concentration (T max) by approximately one hour.

How Doliprane Works (Frovatriptan's Mechanism of Action)

Doliprane, containing Frovatriptan, acts by modulating the body's trigeminovascular system at the molecular and physiological level. Its mechanism involves a dual approach, modulating both the vascular and neuronal components of the trigeminovascular system.

---

Selective Modulation of Serotonin 5- HT1 Receptors

Frovatriptan acts as a selective agonist for the 5- HT1 B and 5- HT1 D receptors, which are located on cranial blood vessels and nerve endings, respectively. This molecular interaction initiates the downstream biological changes that influence subsequent pathway activity.

---

Dual Effect: Vascular Narrowing and Neurogenic Suppression

The activation of 5- HT1 B receptors leads to the vasoconstriction of certain extracerebral arteries. Concurrently, 5- HT1 D activation inhibits the release of pro-inflammatory neuropeptides such as CGRP (Calcitonin Gene-Related Peptide) from trigeminal nerve terminals. This combined action contributes to the modulation of activity within the targeted pathways.

---

Interference with the Mechanistic Cascade

By exerting its effects peripherally and early-centrally, Frovatriptan is relevant in situations where targeted pathway adjustment is required to modify the neurovascular signaling cascade. This mechanism is constrained by the extent of pathway centralization.

How to Use Doliprane (Frovatriptan)

Doliprane, containing Frovatriptan 2.5 mg, is administered via the oral route as a film-coated tablet. This medicine is intended for use on an as-needed basis for the acute management of migraine episodes and is not used for migraine prevention. Established instructions for its administration establish specific limits regarding dosage and timing.

Administration Scope	Administration Guidelines
Initial Dose	A single 2.5 mg tablet should be taken at the onset of the migraine headache pain.
Intake Method	The tablet must be swallowed whole with fluids. It may be taken with or without food.
Re-Dosing	If the headache is relieved but then recurs, a second 2.5 mg dose may be taken, provided a minimum interval of 2 hours has passed since the first dose.
Dose Constraint	The total dose administered must not exceed 7.5 mg (three 2.5 mg tablets) within any 24-hour period.

---

Procedural Constraints and Special Populations

Standard documentation outlines specific conditions for repeated use. If a patient experiences no relief following the first dose, a second dose should not be taken for the same migraine attack. The safety of using Frovatriptan to treat more than four migraine attacks in a 30-day period has not been established.

Regarding specific patient groups, dose adjustments are not required for individuals with renal impairment or mild-to-moderate hepatic impairment. Conversely, the safety and efficacy of the 2.5 mg tablets have not been established for use in patients under 18 years of age.

Research Evidence / Overview of Studies for Doliprane (Frovatriptan)

---

Evidence for Use in Acute Migraine Attacks

Researchers have conducted short-term, double-blind Randomized Controlled Trials (RCTs) and systematic reviews that contributed to the initial clinical evaluation for Frovatriptan. These studies were applied to adult populations (aged 18 to 69 years) evaluated for moderate or severe migraine headache pain. The key outcomes measured included the Headache Response, a defined measure that tracks pain severity change, and the endpoint known as Pain-Free Status. RCTs and subsequent meta-analyses report patterns observed in the studies regarding symptom evolution and examined the recurrence of headache pain over 24- to 48-hour periods.

---

Evidence for Use in Intermittent Migraine Prevention

Frovatriptan was evaluated in dedicated, placebo-controlled RCTs that focused on adult women diagnosed with predictable menstrually related migraine (MRM). Research explored the effects of administering the treatment for a short, predefined period, such as a six-day window around the expected onset of menstruation. Trials reported how the incidence (frequency of occurrence) of MRM attacks evolved in the observed populations during the perimenstrual treatment window.

---

Evidence in Special Populations

Research examining Frovatriptan has primarily involved the adult population, and evidence for certain groups remains insufficient. For the pediatric population (children and adolescents), the research status for safety and effectiveness remains inconclusive. Data for the elderly population (individuals over 65 years of age) remain limited. Although some research monitored physiological strain or stress in this subgroup, the evidence does not establish whether patterns observed are consistent with those reported for the primary study population.

---

What is Still Uncertain About the Research

While a substantial body of evidence exists from randomized trials, key limitations in the research landscape remain. Data for certain groups, particularly children and the elderly, are still insufficient. Additionally, long-term effects are not fully established, as follow-up durations were limited in the primary controlled trials. Research describes that when Frovatriptan was evaluated in head-to-head studies with other triptans, studies reported patterns of variability in the rate at which Headache Response was achieved.

Common questions about Doliprane (FAQ)

---

Q: What should I do if my headache comes back after the first dose?

Regulatory information indicates that if the migraine headache is relieved but returns, a second dose may be considered, provided that at least two hours have passed since the first tablet was administered. The total dosage administered is constrained by the maximum limit specified in the official prescribing information for any 24-hour period.

---

Q: How long does Doliprane take to work?

Regulatory studies provide pharmacokinetic data, which describes how the body absorbs the medicine. These studies indicate that the mean maximum concentration of Frovatriptan in the bloodstream is generally achieved approximately 2 to 4 hours after administration. However, the exact time to pain relief can vary among individuals.

---

Q: What is the difference between Frovatriptan and other triptans?

Official information indicates that Frovatriptan has the longest terminal elimination half-life among the triptan class of medicines. This characteristic is related to its sustained presence in the body over time. Regulatory documents do not provide direct comparisons of effectiveness or safety profiles against other specific triptan products.

---

Q: Are there any foods or drinks I should avoid while taking Doliprane?

Official pharmacokinetic documentation states that food does not significantly alter the total amount of Frovatriptan absorbed. The labeling does not provide a specific list of foods or non-alcoholic drinks to avoid. However, taking the tablet with food is documented to delay the time required for the medicine to reach its peak concentration in the blood by approximately one hour.

---

Q: Can Doliprane be used for tension headaches or cluster headaches?

According to the official prescribing information, Frovatriptan is indicated only for the acute treatment of migraine attacks, specifically those with or without an aura, in adults. The safety and effectiveness of this medicine have not been established for the treatment of other types of headaches, such as cluster headaches.

---

Q: What should I do if I think I've taken too much?

Official regulatory information advises that any suspected overdose of Frovatriptan requires immediate contact with an emergency room or poison control center. There is no specific antidote noted for Frovatriptan overdose, and seeking prompt medical assistance is necessary in such situations.

How to Store and Dispose of Doliprane (Frovatriptan)?

Official regulatory guidelines dictate specific conditions for storing and disposing of Doliprane (Frovatriptan) tablets.

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, below 30 C (86 F).
Protection	Keep in the original package to protect from light and moisture.
Child Safety	Store strictly out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Doliprane must not be disposed of via wastewater or household waste. The medicine should be returned and disposed of according to local regulatory requirements for pharmaceutical waste handling.